IP Verse

Biomarker - EP3250599

The patent EP3250599 was granted to Oxford University Innovation on Apr 14, 2021. The application was originally filed on Jan 28, 2016 under application number EP16702773A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3250599

OXFORD UNIVERSITY INNOVATION
Application Number
EP16702773A
Filing Date
Jan 28, 2016
Status
Opposition Rejected
May 9, 2025
Publication Date
Apr 14, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJan 12, 2022VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2007160611
INTERNATIONAL-SEARCH-REPORTWO2012069433
INTERNATIONAL-SEARCH-REPORTWO2014194274
INTERNATIONAL-SEARCH-REPORTWO9948523
OPPOSITIONEP1904050
OPPOSITIONEP3971212
OPPOSITIONUS2006171951
OPPOSITIONUS6531506
OPPOSITIONUS6693130
OPPOSITIONWO2014194274

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Cineus R., Y. Luo A. Abdel Rahman, D. Boesel, S. Hainbuch1, N. Mueller, C. Romagnani, A. Hegazy, "The impact of OSM on intestinal epithelial cells and barrier functions in health and disease Hannover, Germany", European Journal of Immunology, Wiley-VCH, Hoboken, USA, Hoboken, USA, (20220901), vol. 52, no. S1, doi:10.1002/eji.202270100, ISSN 0014-2980, pages 1 - 480, XP093112938
OPPOSITION- Jalal A. Jazayeri, Aradhana Upadhyay, Ann B. Vernallis, Graeme J. Carroll, "Targeting the Glycoprotein 130 Receptor Subunit to Control Pain and Inflammation", Journal of Interferon & Cytokine Research, Mary Ann Liebert, Inc., (20101201), vol. 30, no. 12, doi:10.1089/jir.2010.0035, ISSN 10799907, pages 865 - 873, XP055143486
OPPOSITION- Sandborn William J., Hanauer Stephen B., "Antitumor Necrosis Factor Therapy for Inflammatory Bowel Disease: A Review of Agents, Pharmacology, Clinical Results, and Safety ", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, Lippincott Williams & Wilkins, US, US , (19990501), vol. 5, no. 2, doi:10.1097/00054725-199905000-00008, ISSN 1078-0998, pages 119 - 133, XP093183143
OPPOSITION- Dambacher J., Beigel F., Seiderer J., Haller D., Goke B., Auernhammer C. J, Brand S., "Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease", Gut microbiota, British medical association , London, UK, UK , vol. 56, no. 9, doi:10.1136/gut.2006.118679, ISSN 0017-5749, pages 1257 - 1265, XP093183140
OPPOSITION- Andersen Nynne Nyboe, "Has the risk of colorectal cancer in inflammatory bowel disease decreased?", World Journal of Gastroenterology, WJG Press, CN, CN , (20130101), vol. 19, no. 43, doi:10.3748/wjg.v19.i43.7561, ISSN 1007-9327, page 7561, XP093183146

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents